Metronidazole Accord Healthcare (Metronidazole)

Metronidazole penetrates susceptible microbial cells and is reduced at the nitro group. The reduced form binds to DNA, causing strand breakage and inhibiting nucleic acid synthesis, which leads to cell death in anaerobic bacteria and protozoa.

The dosage of Metronidazole Accord Healthcare is determined by the prescribing clinician based on the infection type, severity, patient age, weight, and renal or hepatic function. Patients should follow the exact regimen provided on the prescription label.

Safety data for metronidazole in pregnancy are limited, and it is generally avoided unless the potential benefit justifies the risk. The drug can be excreted in breast milk, so caution is advised for nursing mothers, and a healthcare provider should evaluate the risk‑benefit ratio.

To request Metronidazole Accord Healthcare, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic organisms and certain protozoa, offering a narrow spectrum that reduces impact on normal flora compared with broad‑spectrum agents like clindamycin or carbapenems. Its oral formulation and good tissue penetration make it a first‑line choice for many anaerobic infections, though resistance patterns and patient factors may guide alternative selection.

Metronidazole Accord Healthcare tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually with food or a full glass of water to lessen gastrointestinal irritation. Tablets should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse events, though rare, include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, pseudomembranous colitis, and hepatic toxicity. Patients should seek immediate medical attention if they experience neurological symptoms, severe skin reactions, or signs of liver injury.

Metronidazole should be avoided in individuals with a known hypersensitivity to the drug or other nitroimidazole compounds. Caution is also required for patients with severe hepatic or renal impairment, those taking disulfiram, and individuals who consume alcohol during therapy.